Download presentation
Published byJerome Cullipher Modified over 10 years ago
1
Management of the Patient Presenting with Wide Complex Tachycardia
Samir Saba, MD Director, Cardiac Electrophysiology
2
Definition Heart rate > 100 b/min QRS > 120 ms
3
Differential Diagnosis
Supraventricular tachycardia with aberrancy Pre-excited tachycardia Motion artifact Paced rhythm Ventricular tachycardia Idiopathic Non-idiopathic
4
Importance of diagnosing VT
Sensitivity versus Specificity In all patients with WCT, VT is the diagnosis in 80% of cases
5
SVT with aberrancy Typical RBBB Typical LBBB
6
Typical bundle morphology
LBBB RBBB
7
LBBB in AVRT
8
RBBB and AVRT
9
Pre-excited Tachycardia
Manifest versus concealed AP
10
WPW
11
WPW
12
Antidromic AVRT
13
Atrial Flutter with Preexcitation
14
AF with Preexcitation
15
Motion artifact Failure to recognize artifact is common:
94% of internists 58% of cardiologists 38% of EP
16
Motion Artifact Recognize artifact by:
Marching the high frequency signal across the WCT Looking at other available leads
17
Paced ECG
18
Paced ECG Paced Not Paced
19
Ventricular Tachycardia
Idiopathic RVOT VT LVOT VT Lt fascicular VT Non-idiopathic ICM NICM HCM Channelopathy (LQTS, Brugada, etc…)
20
RVOT VT
21
LVOT VT
22
Left fascicular VT
23
Other Classifications for VT
Morphology: Monomorphic Polymorphic Bidirectional Mechanisms: Reentry Automaticity Triggered activity Drug susceptibility: Verapamil sensitive Adenosine sensitive
24
Repetitive VT
25
MMVT
26
Non-idiopathic VT
27
Ventricular Tachycardia
28
Bidirectional VT
29
Mechanisms of VT
30
Approach to Management
History Physical Exam ECG EP Study
31
History Age (if >35 yrs, VT>85%)
Symptoms (palpitations, syncope, LH, diaphoresis, angina, seizures, CA…) Circumstances: N/V/D (electrolytes) PMH: Cardiac disease, MI, CHF, ICD, RF Family history: SCD, arrhythmias Medications: QT prolongation, digoxin, diuretics, etc… Habits: Drugs
32
Physical Examination Hemodynamic Stability Signs of acute CHF
Sternal wound PVD Stroke PM/ICD Evidence of AV dissociation (cannon A waves, marked fluctuations in BP, variable S1 intensity) Maneuvers: CSM, pharmacologic interventions (lidocaine, adenosine, BB, verapamil)
33
Other tests Laboratory tests: K, Mg, plasma concentrations of drugs (dig, procan, etc…) CXR: cardiomegaly Echo: structural abnormalities
34
ECG In NSR: AV dissociation Ischemia Fusion beats Acute MI
During WCT: AV dissociation Fusion beats Capture beats Morphology Width of QRS Morphology of the bundles Electrical axis Precordial concordance In NSR: Ischemia Acute MI Old MI Long QT Brugada pattern LVH Epsilon waves
35
AV dissociation
36
Fusion beat
37
ECG
38
ECG
39
Therapy Acute Management: For the Unstable patient:
Emergent synchronized cardioversion If QRS and T cannot be distinguished then defibrillation Cautious use of sedatives and analgesics For the Stable patient: Class I or III AAD Treatment of associated conditions (ischemia, electrolytes,…) Elective cardioversion Interrogation of ICD or PM if present
40
Therapy Chronic Management: AAD: EPS+/-RFA ICD
class IC or III, if structurally normal hearts class III, if structurally abnormal hearts (with ICD) EPS+/-RFA Stand alone therapy in idiopathic VT Adjunctive therapy (+/-AAD) in ischemic VT ICD For primary and secondary prevention of SCD
41
Indication for EPS
42
EP Study Induce the arrhythmia Activation or Pace mapping Ablation
43
Activation Map for VT
44
RVOT VT: pace map
45
Special Case: NSVT EF≤35%, then ICD EF>40%, no ICD
35%<EF≤40%, then EPS and ICD if EPS+ (MUSTT trial) In all these cases, -blockers and other AAD can be used if NSVT is symptomatic.
46
Summary DDX of WCT includes VT, SVT with aberrancy, preexcited tachycardia, artifact, and paced rhythm. VT accounts for 80% Diagnosis hinges of good history, PE, ECG Acute management depends on stability of patient. In the unstable patient, immediate cardioversion or defibrillation is recommended Long term management armamentarium includes: AAD, Ablation, ICD
47
Holter Monitor in a Mouse
48
EPS in a Mouse
49
Question?…
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.